Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and "BRCAness" Mutations

J Oncol Pract. 2016 Mar;12(3):270-2. doi: 10.1200/JOP.2016.010710.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • BRCA2 Protein / genetics*
  • Carboplatin / administration & dosage
  • Female
  • Germ-Line Mutation
  • Humans
  • Middle Aged
  • Phthalazines / administration & dosage
  • Piperazines / administration & dosage
  • Treatment Outcome
  • Triple Negative Breast Neoplasms / diagnosis*
  • Triple Negative Breast Neoplasms / drug therapy
  • Triple Negative Breast Neoplasms / genetics

Substances

  • BRCA2 Protein
  • BRCA2 protein, human
  • Phthalazines
  • Piperazines
  • Carboplatin
  • olaparib